Table of Contents Table of Contents
Previous Page  398 / 1851 Next Page
Information
Show Menu
Previous Page 398 / 1851 Next Page
Page Background

Monoclonal antibodies

Small molecules

(e.g. tyrosine kinase inhibitors)

How do we target key structures?